Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen
Background The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of natur...
Gespeichert in:
| Veröffentlicht in: | Veterinary record 2022-02, Vol.190 (4), p.no-no |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | no |
|---|---|
| container_issue | 4 |
| container_start_page | no |
| container_title | Veterinary record |
| container_volume | 190 |
| creator | De Koster, Jenne Tena, Jezaniah‐Kira Stegemann, Michael R. |
| description | Background
The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD.
Methods
Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin‐ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post‐treatment. Individual respiration and depression scores were determined at 6 h post‐treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21.
Results
The tulathromycin‐ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin‐ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin‐ketoprofen‐treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score).
Conclusion
Efficacy of tulathromycin‐ketoprofen for the treatment of BRD was non‐inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare. |
| doi_str_mv | 10.1002/vetr.834 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2569383923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2569383923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3834-b9217b33c87139cf5d23887c336ef764801ca2be032052fdfffd9ca133398cde3</originalsourceid><addsrcrecordid>eNp1kNFqFTEQhoNY7Gkr-AQS8MabrUlmz2b3UkrVQkGQ096GbDKxqbvJMcm2nLc3S6uC4NXMxTff_PyEvOHsnDMmPjxgSec9tC_IRrBWNLKT7CXZsHVvB8aOyUnO95UctiBekWNoW9n1XG6I3SXUZcZQaHR0jA8-IE2Y9z7pEtOBWp9RZ6SPvtxRTbMP3yek2s4--Fwq5GNYT8sy6XKX4nwwPlAdLP2BJe5TdBjOyJHTU8bXz_OU3Hy63F18aa6_fr66-HjdGKjhm3EQXI4AppccBuO2VkDfSwPQoZNd2zNutBiRgWBb4axzzg5GcwAYemMRTsn7J299-3PBXNTss8Fp0gHjkpXYdkP9NAio6Lt_0Pu4pFDTKdEBk1wIKf8KTYo5J3Rqn_ys00Fxptbm1dq8quEr-vZZuIwz2j_g76or0DwBj37Cw39F6vZy920V_gJvXI6O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630712277</pqid></control><display><type>article</type><title>Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>De Koster, Jenne ; Tena, Jezaniah‐Kira ; Stegemann, Michael R.</creator><creatorcontrib>De Koster, Jenne ; Tena, Jezaniah‐Kira ; Stegemann, Michael R.</creatorcontrib><description>Background
The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD.
Methods
Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin‐ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post‐treatment. Individual respiration and depression scores were determined at 6 h post‐treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21.
Results
The tulathromycin‐ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin‐ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin‐ketoprofen‐treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score).
Conclusion
Efficacy of tulathromycin‐ketoprofen for the treatment of BRD was non‐inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.</description><identifier>ISSN: 0042-4900</identifier><identifier>EISSN: 2042-7670</identifier><identifier>DOI: 10.1002/vetr.834</identifier><identifier>PMID: 34476817</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; Anti-Bacterial Agents - therapeutic use ; bovine respiratory disease ; Cattle ; Cattle Diseases - drug therapy ; Disaccharides - therapeutic use ; Heterocyclic Compounds - therapeutic use ; Ketoprofen - therapeutic use ; Respiration ; Respiratory diseases ; treatment ; Veterinary medicine</subject><ispartof>Veterinary record, 2022-02, Vol.190 (4), p.no-no</ispartof><rights>2021 Zoetis. published by John Wiley & Sons Ltd on behalf of British Veterinary Association</rights><rights>2021 Zoetis. Veterinary Record published by John Wiley & Sons Ltd on behalf of British Veterinary Association.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3834-b9217b33c87139cf5d23887c336ef764801ca2be032052fdfffd9ca133398cde3</citedby><cites>FETCH-LOGICAL-c3834-b9217b33c87139cf5d23887c336ef764801ca2be032052fdfffd9ca133398cde3</cites><orcidid>0000-0002-2891-0298</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fvetr.834$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fvetr.834$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34476817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Koster, Jenne</creatorcontrib><creatorcontrib>Tena, Jezaniah‐Kira</creatorcontrib><creatorcontrib>Stegemann, Michael R.</creatorcontrib><title>Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen</title><title>Veterinary record</title><addtitle>Vet Rec</addtitle><description>Background
The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD.
Methods
Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin‐ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post‐treatment. Individual respiration and depression scores were determined at 6 h post‐treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21.
Results
The tulathromycin‐ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin‐ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin‐ketoprofen‐treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score).
Conclusion
Efficacy of tulathromycin‐ketoprofen for the treatment of BRD was non‐inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>bovine respiratory disease</subject><subject>Cattle</subject><subject>Cattle Diseases - drug therapy</subject><subject>Disaccharides - therapeutic use</subject><subject>Heterocyclic Compounds - therapeutic use</subject><subject>Ketoprofen - therapeutic use</subject><subject>Respiration</subject><subject>Respiratory diseases</subject><subject>treatment</subject><subject>Veterinary medicine</subject><issn>0042-4900</issn><issn>2042-7670</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kNFqFTEQhoNY7Gkr-AQS8MabrUlmz2b3UkrVQkGQ096GbDKxqbvJMcm2nLc3S6uC4NXMxTff_PyEvOHsnDMmPjxgSec9tC_IRrBWNLKT7CXZsHVvB8aOyUnO95UctiBekWNoW9n1XG6I3SXUZcZQaHR0jA8-IE2Y9z7pEtOBWp9RZ6SPvtxRTbMP3yek2s4--Fwq5GNYT8sy6XKX4nwwPlAdLP2BJe5TdBjOyJHTU8bXz_OU3Hy63F18aa6_fr66-HjdGKjhm3EQXI4AppccBuO2VkDfSwPQoZNd2zNutBiRgWBb4axzzg5GcwAYemMRTsn7J299-3PBXNTss8Fp0gHjkpXYdkP9NAio6Lt_0Pu4pFDTKdEBk1wIKf8KTYo5J3Rqn_ys00Fxptbm1dq8quEr-vZZuIwz2j_g76or0DwBj37Cw39F6vZy920V_gJvXI6O</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>De Koster, Jenne</creator><creator>Tena, Jezaniah‐Kira</creator><creator>Stegemann, Michael R.</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2891-0298</orcidid></search><sort><creationdate>20220201</creationdate><title>Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen</title><author>De Koster, Jenne ; Tena, Jezaniah‐Kira ; Stegemann, Michael R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3834-b9217b33c87139cf5d23887c336ef764801ca2be032052fdfffd9ca133398cde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>bovine respiratory disease</topic><topic>Cattle</topic><topic>Cattle Diseases - drug therapy</topic><topic>Disaccharides - therapeutic use</topic><topic>Heterocyclic Compounds - therapeutic use</topic><topic>Ketoprofen - therapeutic use</topic><topic>Respiration</topic><topic>Respiratory diseases</topic><topic>treatment</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Koster, Jenne</creatorcontrib><creatorcontrib>Tena, Jezaniah‐Kira</creatorcontrib><creatorcontrib>Stegemann, Michael R.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary record</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Koster, Jenne</au><au>Tena, Jezaniah‐Kira</au><au>Stegemann, Michael R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen</atitle><jtitle>Veterinary record</jtitle><addtitle>Vet Rec</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>190</volume><issue>4</issue><spage>no</spage><epage>no</epage><pages>no-no</pages><issn>0042-4900</issn><eissn>2042-7670</eissn><abstract>Background
The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD.
Methods
Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin‐ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post‐treatment. Individual respiration and depression scores were determined at 6 h post‐treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21.
Results
The tulathromycin‐ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin‐ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin‐ketoprofen‐treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score).
Conclusion
Efficacy of tulathromycin‐ketoprofen for the treatment of BRD was non‐inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34476817</pmid><doi>10.1002/vetr.834</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2891-0298</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-4900 |
| ispartof | Veterinary record, 2022-02, Vol.190 (4), p.no-no |
| issn | 0042-4900 2042-7670 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2569383923 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Anti-Bacterial Agents - therapeutic use bovine respiratory disease Cattle Cattle Diseases - drug therapy Disaccharides - therapeutic use Heterocyclic Compounds - therapeutic use Ketoprofen - therapeutic use Respiration Respiratory diseases treatment Veterinary medicine |
| title | Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A44%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20bovine%20respiratory%20disease%20with%20a%20single%20administration%20of%20tulathromycin%20and%20ketoprofen&rft.jtitle=Veterinary%20record&rft.au=De%20Koster,%20Jenne&rft.date=2022-02-01&rft.volume=190&rft.issue=4&rft.spage=no&rft.epage=no&rft.pages=no-no&rft.issn=0042-4900&rft.eissn=2042-7670&rft_id=info:doi/10.1002/vetr.834&rft_dat=%3Cproquest_cross%3E2569383923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630712277&rft_id=info:pmid/34476817&rfr_iscdi=true |